Evidence map›Paper›PMID 20371606›Full record

ArticleThe Journal of biological chemistry2010

Activation of AP-1 transcription factors differentiates FGF2 and vascular endothelial growth factor regulation of endothelial nitric-oxide synthase expression in placental artery endothelial cells.

Eugenia Mata-Greenwood, Wu-xiang Liao, Wen Wang, Jing Zheng, Dong-bao Chen

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Estradiol-17β stimulates HJournal of cellular physiology · 2019
    Article
  3. Article
  4. Article
  5. Article
  6. Regulation of placental angiogenesis.Microcirculation (New York, N.Y. : 1994) · 2014
    Review
  7. Article
  8. Signaling regulation of fetoplacental angiogenesis.The Journal of endocrinology · 2012
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Eugenia Mata-GreenwoodDepartment of Reproductive Medicine, University of California San Diego, La Jolla, California 92093, USA.
Wu-xiang Liao
Wen Wang
Jing Zheng
Dong-bao Chen
University of California, San Diego · USUniversity of California, Irvine · USUniversity of Wisconsin–Madison · US

Funding

Actions of Estrogen on Uterine Artery EndotheliumR01HL070562 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, DONGBAO · 2001 to 2025
$6.3M
EFFECTS OF NITRIC OXIDE ON FETOPLACENTAL ANGIOGENESISR01HL064703 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI ZHENG, JING · 2000 to 2008
$1.9M
Caveolin-1, Caveolae and Placental AngiogenesisR01HL074947 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, DONGBAO · 2004 to 2007
$1.3M
NHLBI NIH HHS HL70562NHLBI NIH HHS R01 HL064703NHLBI NIH HHS R01 HL070562NHLBI NIH HHS R01 HL074947NHLBI NIH HHS R01 HL64703NHLBI NIH HHS R01 HL74947
6 · The paper itself

Abstract

FGF2 (fibroblast growth factor 2), but not vascular endothelial growth factor (VEGF), stimulates sustained activation of ERK2/1 for endothelial NOS3 (nitric-oxide synthase 3) protein expression in ovine fetoplacental artery endothelial cells (oFPAEC). We deciphered herein the downstream signaling of ERK2/1 responsible for NOS3 expression by FGF2 in oFPAEC. FGF2, but not VEGF, increased NOS3 mRNA levels without altering its degradation. FGF2, but not VEGF, trans-activated sheep NOS3 promoter, and this was dependent on ERK2/1 activation. FGF2 did not trans-activate NOS3 promoters with deletions upstream of the consensus AP-1 site (TGAGTC A, -678 to -685). Trans-activation of wild-type NOS3 promoter by FGF2 was significantly inhibited when either the AP-1 or the cAMP-response element (CRE)-like sequence (TGCGTCA, -752 to -758) was mutated and was completely blocked when both were mutated. EMSA analyses showed that FGF2, but not VEGF, stimulated AP-1 and CRE DNA-protein complexes primarily composed of JunB and Fra1. Chromatin immunoprecipitation assays confirmed JunB/Fra1 binding to NOS3 promoter AP-1 and CRE elements in intact cells. FGF2, but not VEGF, stimulated JunB and Fra1 expressions; all preceded NOS3 up-regulation and were inhibited by PD98059. Down-regulation of JunB or Fra-1, but not c-Jun, blocked FGF2 stimulation of NOS3 expression and NO production. AP-1 inhibition suppressed FGF2 stimulation of NOS3 expression in human umbilical vein EC and uterine artery endothelial cells. Thus, FGF2 induction of NOS3 expression is mainly mediated by AP-1-dependent transcription involving JunB and Fra1 up-regulation via sustained ERK2/1 activation in endothelial cells.

Indexed as

AnimalsArteriesEndothelial CellsFemaleFibroblast Growth Factor 2HumansModels, BiologicalNitric Oxide Synthase Type IIIPlacentaPregnancyPregnancy, AnimalSheepTranscriptional ActivationTranscription Factor AP-1Vascular Endothelial Growth Factor AFibroblast Growth Factor 2Nitric Oxide Synthase Type IIITranscription Factor AP-1Vascular Endothelial Growth Factor A

Identifiers

PMID20371606
PMCPMC2878498
OpenAlexW1998683777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.